GlassScriptPhysician profile
Duane C Kuentz
NPI 1366531071
$3,280.82
in general payments reported to CMS, 2019-2025
34 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $995 · 2020: $246 · 2021: $33.97 · 2022: $437 · 2023: $605 · 2024: $515 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,568.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $517.48 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $341.29 | 2019-2025 | Breztri, Farxiga |
| Abbvie INC. | $288.06 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $271.92 | 2022-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $249.64 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $194.04 | 2019-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $171.58 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $118.71 | 2019-2024 | |
| Amarin Pharma, INC. | $112.56 | 2019-2020 | |
| Abbott Laboratories | $94.24 | 2023-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $82.14 | 2019-2025 | Verquvo, Steglatro, Capvaxive |
| Amgen INC. | $81.95 | 2019-2025 | Repatha, Evenity |
| Astellas Pharma US INC | $77.17 | 2019-2024 | Veozah |
| Novo Nordisk INC | $74.44 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Allergan, INC. | $70.07 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $52.57 | 2019 | |
| Vertical Pharmaceuticals, LLC | $52.44 | 2019 | |
| Sunovion Pharmaceuticals INC. | $48.55 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $42.99 | 2023 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $41.76 | 2025 | Voquezna |
| Mylan Specialty L.P. | $37.25 | 2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $31.80 | 2019 | |
| Avanir Pharmaceuticals, INC. | $30.96 | 2019 | |
| Pulmonx Corporation | $25.84 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Exact Sciences Corporation | $25.26 | 2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $23.75 | 2022 | |
| Axsome Therapeutics, INC. | $20.29 | 2025 | Auvelity |
| Viiv Healthcare Company | $19.75 | 2025 | Apretude |
| Dynavax Technologies Corporation | $18.76 | 2024 | Heplisav-B |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.02 | 2019 | |
| Xeris Pharmaceuticals, INC. | $13.57 | 2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $12.81 | 2020 | |
| Phadia US INC. | $11.60 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duane Kuentz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.